CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells

CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells

Abstract Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is a new promising target for the treatment of ovarian cancer. Our previous study showed that cross‐reacting material 197 (CRM197), a specific HB‐EGF inhibitor, significantly reverses resistance against paclitaxel in paclit...

Full description

Bibliographic Details
Main Authors: Xiao‐han Tang, Hui Li, Xiu‐shuang Zheng, Mei‐song Lu, Yuan An, Xiao‐lei Zhang
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Medicine
Subjects:
CRM197
HB‐EGF
NAC‐1
ovarian cancer
paclitaxel resistance
Online Access:https://doi.org/10.1002/cam4.2512

Internet

https://doi.org/10.1002/cam4.2512

Similar Items